{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:29:29Z","timestamp":1760920169716,"version":"build-2065373602"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,19]]},"DOI":"10.7759\/cureus.94907","type":"journal-article","created":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T10:47:30Z","timestamp":1760870850000},"source":"Crossref","is-referenced-by-count":0,"title":["Systemic Therapies for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Sahar Khalil","family":"Hamza Osman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malaz Awad","family":"Mohamed Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoda","family":"Idrees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziza Mohammad Hassan","family":"Mohammad Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aisha Hassan","family":"Ahmed Taha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima Hassan","family":"Musa Shaikhelsafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afrah Mohamed","family":"Mirghani Hamour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/life11090936","article-title":"The epidemiology and global burden of atopic dermatitis: a narrative review","volume":"11","author":"Hadi HA","year":"2021","unstructured":"Hadi HA, Tarmizi AI, Khalid KA, Gajd\u00e1cs M, Aslam A, Jamshed S. The epidemiology and global burden of atopic dermatitis: a narrative review. Life (Basel). 2021, 11:936. 10.3390\/life11090936","journal-title":"Life (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2023.0011","article-title":"Atopic dermatitis in children and adults: diagnosis and treatment","volume":"120","author":"Wollenberg A","year":"2023","unstructured":"Wollenberg A, Werfel T, Ring J, Ott H, Gieler U, Weidinger S. Atopic dermatitis in children and adults: diagnosis and treatment. Dtsch Arztebl Int. 2023, 120:224-34. 10.3238\/arztebl.m2023.0011","journal-title":"Dtsch Arztebl Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.yapd.2023.03.006","article-title":"Update on atopic dermatitis","volume":"70","author":"Kellogg C","year":"2023","unstructured":"Kellogg C, Smogorzewski J. Update on atopic dermatitis. Adv Pediatr. 2023, 70:157-70. 10.1016\/j.yapd.2023.03.006","journal-title":"Adv Pediatr"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2022.43.220076","article-title":"Treatment options for moderate to severe atopic dermatitis","volume":"43","author":"Wallace DV","year":"2022","unstructured":"Wallace DV. Treatment options for moderate to severe atopic dermatitis. Allergy Asthma Proc. 2022, 43:474-93. 10.2500\/aap.2022.43.220076","journal-title":"Allergy Asthma Proc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.51560","article-title":"Management of atopic dermatitis: a narrative review","volume":"216","author":"Goh MS","year":"2022","unstructured":"Goh MS, Yun JS, Su JC. Management of atopic dermatitis: a narrative review. Med J Aust. 2022, 216:587-93. 10.5694\/mja2.51560","journal-title":"Med J Aust"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/ijpd.ijpd_83_21","article-title":"A comprehensive review of immunosuppressive drugs in pediatric dermatoses: part I - corticosteroids, azathioprine, and cyclosporine - A","volume":"23","author":"Bose S","year":"2022","unstructured":"Bose S, Madke B. A comprehensive review of immunosuppressive drugs in pediatric dermatoses: part I - corticosteroids, azathioprine, and cyclosporine - A. Indian J Paediatr Dermatol. 2022, 23:191-203. 10.4103\/ijpd.ijpd_83_21","journal-title":"Indian J Paediatr Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010781","article-title":"Immunopathogenesis of atopic dermatitis: focus on interleukins as disease drivers and therapeutic targets for novel treatments","volume":"24","author":"Makowska K","year":"2023","unstructured":"Makowska K, Nowaczyk J, Blicharz L, Wa\u015bkiel-Burnat A, Czuwara J, Olszewska M, Rudnicka L. Immunopathogenesis of atopic dermatitis: focus on interleukins as disease drivers and therapeutic targets for novel treatments. Int J Mol Sci. 2023, 24:781. 10.3390\/ijms24010781","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15327","article-title":"Methotrexate for inflammatory skin disease in pediatric patients: consensus treatment guidelines","volume":"40","author":"Siegfried EC","year":"2023","unstructured":"Siegfried EC, Arkin LM, Chiu YE, et al.. Methotrexate for inflammatory skin disease in pediatric patients: consensus treatment guidelines. Pediatr Dermatol. 2023, 40:789-808. 10.1111\/pde.15327","journal-title":"Pediatr Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-014-0084-2","article-title":"Long-term safety of immunomodulators in pediatric inflammatory diseases","volume":"16","author":"Nuti F","year":"2014","unstructured":"Nuti F, Civitelli F, Cucchiara S. Long-term safety of immunomodulators in pediatric inflammatory diseases. Paediatr Drugs. 2014, 16:343-52. 10.1007\/s40272-014-0084-2","journal-title":"Paediatr Drugs"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01484-1","article-title":"Clinically meaningful improvements in adolescents with moderate-to-severe atopic dermatitis treated with tralokinumab who did not achieve clear or almost clear skin at week 16","volume":"15","author":"Paller AS","year":"2025","unstructured":"Paller AS, Blauvelt A, Soong W, Chih-Ho Hong H, Schuttelaar ML, Schneider SK, Simpson EL. Clinically meaningful improvements in adolescents with moderate-to-severe atopic dermatitis treated with tralokinumab who did not achieve clear or almost clear skin at week 16. Dermatol Ther (Heidelb). 2025, 15:2879-96. 10.1007\/s13555-025-01484-1","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2024.04.006","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled phase 3 study","volume":"73","author":"Ebisawa M","year":"2024","unstructured":"Ebisawa M, Kataoka Y, Tanaka A, et al.. Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled phase 3 study. Allergol Int. 2024, 73:532-42. 10.1016\/j.alit.2024.04.006","journal-title":"Allergol Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02998-4","article-title":"Dupilumab is efficacious in young children with atopic dermatitis regardless of type 2 comorbidities","volume":"41","author":"Boguniewicz M","year":"2024","unstructured":"Boguniewicz M, Sher LD, Paller AS, et al.. Dupilumab is efficacious in young children with atopic dermatitis regardless of type 2 comorbidities. Adv Ther. 2024, 41:4601-16. 10.1007\/s12325-024-02998-4","journal-title":"Adv Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/all.16512","article-title":"Integrated efficacy and safety analysis of abrocitinib in adolescents with moderate-to-severe atopic dermatitis","volume":"80","author":"Paller AS","year":"2025","unstructured":"Paller AS, Eichenfield LF, Irvine AD, et al.. Integrated efficacy and safety analysis of abrocitinib in adolescents with moderate-to-severe atopic dermatitis. Allergy. 2025, 80:2213-24. 10.1111\/all.16512","journal-title":"Allergy"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.3696","article-title":"Upadacitinib in adolescents with moderate to severe atopic dermatitis: analysis of 3 phase 3 randomized clinical trials through 76 weeks","volume":"160","author":"Paller AS","year":"2024","unstructured":"Paller AS, Mendes-Bastos P, Siegfried E, et al.. Upadacitinib in adolescents with moderate to severe atopic dermatitis: analysis of 3 phase 3 randomized clinical trials through 76 weeks. JAMA Dermatol. 2024, 160:1304-13. 10.1001\/jamadermatol.2024.3696","journal-title":"JAMA Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00842-7","article-title":"Safety and efficacy of upadacitinib for atopic dermatitis in Japan: 2-year interim results from the phase 3 rising up study","volume":"13","author":"Katoh N","year":"2023","unstructured":"Katoh N, Ohya Y, Murota H, et al.. Safety and efficacy of upadacitinib for atopic dermatitis in Japan: 2-year interim results from the phase 3 rising up study. Dermatol Ther (Heidelb). 2023, 13:221-34. 10.1007\/s13555-022-00842-7","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2021.11.001","article-title":"A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (rising up): an interim 24-week analysis","volume":"6","author":"Katoh N","year":"2022","unstructured":"Katoh N, Ohya Y, Murota H, et al.. A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (rising up): an interim 24-week analysis. JAAD Int. 2022, 6:27-36. 10.1016\/j.jdin.2021.11.001","journal-title":"JAAD Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich K","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, et al.. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021, 397:2169-81. 10.1016\/S0140-6736(21)00589-4","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky E","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et al.. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021, 397:2151-68. 10.1016\/S0140-6736(21)00588-2","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2830","article-title":"Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial","volume":"157","author":"Eichenfield LF","year":"2021","unstructured":"Eichenfield LF, Flohr C, Sidbury R, et al.. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. 2021, 157:1165-73. 10.1001\/jamadermatol.2021.2830","journal-title":"JAMA Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Silverberg JI","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, et al.. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020, 156:863-73. 10.1001\/jamadermatol.2020.1406","journal-title":"JAMA Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson EL","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, et al.. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020, 396:255-66. 10.1016\/S0140-6736(20)30732-7","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.854","article-title":"Dupilumab provides rapid and sustained improvement in scoring atopic dermatitis outcomes in paediatric patients with atopic dermatitis","volume":"102","author":"Wollenberg A","year":"2022","unstructured":"Wollenberg A, Marcoux D, Silverberg JI, et al.. Dupilumab provides rapid and sustained improvement in scoring atopic dermatitis outcomes in paediatric patients with atopic dermatitis. Acta Derm Venereol. 2022, 102:adv00726. 10.2340\/actadv.v102.854","journal-title":"Acta Derm Venereol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson EL","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, et al.. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020, 156:44-56. 10.1001\/jamadermatol.2019.3336","journal-title":"JAMA Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich K","year":"2021","unstructured":"Reich K, Papp KA, Blauvelt A, et al.. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021, 397:487-98. 10.1016\/S0140-6736(21)00125-2","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber T","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, et al.. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021, 384:1101-12. 10.1056\/NEJMoa2019380","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16156","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9)","volume":"178","author":"de Bruin-Weller M","year":"2018","unstructured":"de Bruin-Weller M, Tha\u00e7i D, Smith CH, et al.. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9). Br J Dermatol. 2018, 178:1083-101. 10.1111\/bjd.16156","journal-title":"Br J Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.2192","article-title":"Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update","volume":"160","author":"Drucker AM","year":"2024","unstructured":"Drucker AM, Lam M, Prieto-Merino D, et al.. Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update. JAMA Dermatol. 2024, 160:936-44. 10.1001\/jamadermatol.2024.2192","journal-title":"JAMA Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller AS","year":"2022","unstructured":"Paller AS, Simpson EL, Siegfried EC, et al.. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022, 400:908-19. 10.1016\/S0140-6736(22)01539-2","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18345","article-title":"European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy","volume":"36","author":"Wollenberg A","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, et al.. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022, 36:1409-31. 10.1111\/jdv.18345","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/420781-systemic-therapies-for-moderate-to-severe-atopic-dermatitis-in-children-and-adolescents-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T10:47:31Z","timestamp":1760870851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/420781-systemic-therapies-for-moderate-to-severe-atopic-dermatitis-in-children-and-adolescents-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,19]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.94907","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,19]]}}}